Althesin will control status epilepticus when other agents fail. Its major advantage over other agents is its lack of accumulation because it is readily metabolized. Three patients are reported and relevant literature is discussed.
INTRODUCTION
Althesin is widely regarded as being contraindicated in epileptic patients. This has resulted from reports of clonic convulsions which occasionally occur immediately after administration of althesin. We report the use of althesin to control convulsions in refractory status epilepticus.
Case 1:
A 23-year-old epileptic woman became very unstable on her oral medications requiring 13 admissions to hospital in 24 months. A typical regime was mysoline 375 mg and clonazepam 3 mg four times daily, and phenytoin 100 mg twice daily. On most admissions, status was controlled with intravenous diazepam until background medications could be adjusted. On various occasions, intravenous phenytoin, intramuscular paraldehyde, thiopentone infusions and even hypothermia with intermittent positive pressure ventilation (I.P.P.V.) were tried witch mixed results. Thiopentone in amounts needed to control fitting, accumulated and caused depression of reflexes with sputum retention.
On one occasion she had diazepam 300 mg intravenously over 12 hours and was still fitting regularly. She was given althesin 3 ml intravenously as a trial and immediately stopped fitting. She was then given a continuous infusion of aIthesin 50 ml in one litre of saline at 80 ml/hr which was gradually reduced as she remained without convulsions. A similar pattern was repeated on other occasions.
Case 2:
A 17-year-old male was admitted in status epilepticus. His usual therapy was phenytoin 400 mg daily, tegretol 200 mg and clonazepam 4 mg three times daily. These were continued via a N/G tube. He was given diazepam 20 mg intravenously and a further 160 mg over the first 24 hours, 260 mg in the second 24 hours and 300 mg in the third 24 hours. Although deeply sedated he continued to have regular convulsions.
He was then given althesin. A solution containing 50 ml of althesin added to one litre of saline was given via an infusion pump. The rate of infusion was adjusted according to the presence of fitting. When the patient showed localized twitching the infusion rate was increased, and if no twitching occurred for one hour then the infusion rate was reduced by 10 ml/hr. A typical rate was 30 ml/hr. Over a period of 55 hours, 890 ml of the above mixture was used. During the periods when the patient was not fitting he was drowsy but would answer when spoken to, except for the first 24 hours following the diazepam.
Case 3:
A 17-year-old male epileptic taking tegretol 1000 mg and phenytoin 300 mg daily, arrived in hospital with status epilepticus. He was given diazepam 30 mg intramuscularly by his family doctor three-quarters of an hour prior to admission. On arrival because he was still Anaeslhesia alld llllel1.lire Care, Vol. VIT, No. I, February, 1979 fitting, a further SO mg of diazepam was given intravenously over three-quarters of an hour without adequate control. His respiration was significantly depressed however. Althesin 3 ml was given intravenously and he immediately stopped fitting. A mixture of 2S ml of althesin in SOO ml dextrose/saline was made up and the patient was given a slow bolus of 10-30 ml whenever he fitted. The amount given each time was determined by when the fits stopped. Over the next 34 hours he received bolus injections totalling 230 ml (11.S ml althesin). Following each bolus injection fitting would stop and the patient would respond to spoken command. His oral anti-epileptic medications were adjusted, and as his fitting was controlled the althesin was discontinued.
INFUSION REGIME
The infusion protocol we have developed is simple. Althesin SO ml is placed in one litre of crystalloid fluid (i.e. 20 ml of solution contains 1 ml of althesin). For safety we give the infusion via a paediatric burette and infusion pump.
An initial bolus of 1-3 ml of pure althesin is given if the patient is fitting. This dose will nearly always stop the fitting. 'J1he infusion is then started at 40-S0 ml/hour (i.e. 2-2.S ml althesin/hour). If a further fit occurs, a 20 ml bolus of fluid can be given and the rate adiusted. In the absence of convulsions the infusion rate is gradually decreased.
We have found the system workable and easily administered by nursing staff.
DISCUSSION
There have been seven cases of althesin induced convulsions reported in the literature (Uppington 1973 , Rees 1975 , McGowan 1976 , Evans and Keogh 1977 None of these patients had a history of convulsions or eoilepsy. The case reported by Uppington is the only one where an EEG done postooeratively showed subclinical epileptic spike discharges. Evans and Keogh (1977) reported four cases of convulsions in a retrospective survey of approximately 19,000 administrations.
From these reports it has been concluded that althesin is contraindicated in epileptic natients on the surmise that althesin may be like methohexitone and hydroxydione and facilitate epileotic discharges. However, l'he evidence for this is slim and rests on one group who showed enhancement of epiIeptiform EEG change after althesin in patients with pre-existing intracranial disease and previously detected EEG changes (Commelli, Pignatelli and Varassi 1977) .
In general the changes in the EEG are similar after aIthesin to those produced by other anaesthetics. The first effect of the drug is a mixture of fast theta and delta activity, followed by fast high voltage delta activity alone.
With deeper anaesthesia one finds partial, definite, and later well established burst suppression patterns (Scott and Virden 1972) . In one of our cases an EEG was done before and after althesin while the patient was paralysed and ventilated. The trace developed a general flattening and loss of spike activity.
Clonic muscular movements following induction with althesin are a recognized complication especially in response to stimulation (Swerdlow, Chakreborty and Zahangir 1971) . Suoh reactions seem to be related to dose, rate of injection, and premedication (Samuel and Dundee 1973, Clarke et al. 1972) . However, EEGs taken during such clonic movements have not shown spike activity (Laxenaire et al. 1974) . Thus it must be a possibility that convulsions described are due to exaggeration of other effects rather than discharge of incipient epileptic foci.
It is possible that althesin may displace phenytoin from its protein binding site and exert its effect via phenytoin. Althesin is readily bound to serum proteins (J ones 1972) . Another interesting fact is that some agents known to cause convulsions can act as anticonvulsants e.g. Lignocaine (Westreich and Kneller 1972) .
Althesin has two advantages over its barbiturate counterparts. Firstly, it has a greater therapeutic ratio and thus a greater margin of ~afetv. Secondly, rapid elimination from the blood by the liver occurs so that recovery does not rely on redistribution (Davis and Pearce 1972) . The non-accumulative property was si~nificant in our use of althesin in that it allowed finger tip control of depth of sedation avoiding the problems which occur with the gradual tissue accumulation of diazepam and th i ()I)entone.
Unfortunately there have been numerous reports of adverse reactions to althesin, the most serious of which is an occasional severe histaminoid reaction. The overall incidence of comolications will possibly make the af!ent unaccentable (Evans and Keogh 1977) . HvoerIioidaemia following long term continuol1<: infusion of althesin has been reported by Forrest, Watrasiewics and Moore ( 1977) , who recommend monitoring of plasma lipids. This may yet prove a significant problem in long term infusion.
In conclusion, we have found althesin to be a useful non-accumulative drug in control of severe refractory epilepsy. We believe the evidence against using it in epileptic patients to be slim at this stage. In practice the drug is predictable in its control of convulsions and easy to use. We do not advocate it as the drug of first choice but suggest it is an effective addition to drugs which are available to control status epilepticus.
